{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:24:14Z","timestamp":1791390254625,"version":"4.3.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82201555"],"award-info":[{"award-number":["82201555"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong","doi-asserted-by":"crossref","award":["2022A1515010478"],"award-info":[{"award-number":["2022A1515010478"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04063-1","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T08:24:33Z","timestamp":1740558273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neuro intensive care unit"],"prefix":"10.1186","volume":"25","author":[{"given":"Fangyi","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunsha","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunzhou","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiezhen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"issue":"1","key":"4063_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","volume":"68","author":"B Claytor","year":"2023","unstructured":"Claytor B, Cho S, Li Y. Myasthenic crisis. Muscle Nerve. 2023;68(1):8\u201319. https:\/\/doi.org\/10.1002\/mus.27832.","journal-title":"Muscle Nerve"},{"issue":"3","key":"4063_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322. https:\/\/doi.org\/10.1212\/WNL.0000000000011124.","journal-title":"Neurology"},{"issue":"9A","key":"4063_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1590\/0004-282X20130108","volume":"71","author":"DA Godoy","year":"2013","unstructured":"Godoy DA, de Mello LJV, Masotti L, Di Napoli M. The myasthenic patient in crisis: an update of the management in Neurointensive Care Unit. Arq Neuropsiquiatr. 2013;71(9A):627\u201339. https:\/\/doi.org\/10.1590\/0004-282X20130108.","journal-title":"Arq Neuropsiquiatr"},{"issue":"7","key":"4063_CR4","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/ene.12703","volume":"22","author":"A Ramos-Fransi","year":"2015","unstructured":"Ramos-Fransi A, Rojas-Garc\u00eda R, Segovia S, et al. Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry. Eur J Neurol. 2015;22(7):1056\u201361. https:\/\/doi.org\/10.1111\/ene.12703.","journal-title":"Eur J Neurol"},{"issue":"6","key":"4063_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","volume":"94","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Suzuki S, Kuwabara S, et al. Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2023;94(6):467\u201373. https:\/\/doi.org\/10.1136\/jnnp-2022-330519.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"4063_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primer. 2019;5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y.","journal-title":"Nat Rev Dis Primer"},{"issue":"2","key":"4063_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","volume":"21","author":"MG Huijbers","year":"2022","unstructured":"Huijbers MG, Marx A, Plomp JJ, Le Panse R, Phillips WD. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):163\u201375. https:\/\/doi.org\/10.1016\/S1474-4422(21)00357-4.","journal-title":"Lancet Neurol"},{"issue":"23","key":"4063_CR8","doi-asserted-by":"publisher","first-page":"12943","DOI":"10.1073\/pnas.2004325117","volume":"117","author":"S Borghi","year":"2020","unstructured":"Borghi S, Bournazos S, Thulin NK, et al. FcRn, but not Fc\u03b3Rs, drives maternal-fetal transplacental transport of human IgG antibodies. Proc Natl Acad Sci U S A. 2020;117(23):12943\u201351. https:\/\/doi.org\/10.1073\/pnas.2004325117.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4063_CR9","doi-asserted-by":"publisher","first-page":"728322","DOI":"10.3389\/fimmu.2021.728322","volume":"12","author":"C Monnet","year":"2021","unstructured":"Monnet C, Jacque E, de Romeuf C, et al. The dual targeting of FcRn and Fc\u03b3Rs via Monomeric Fc Fragments Results in strong inhibition of IgG-Dependent autoimmune pathologies. Front Immunol. 2021;12:728322. https:\/\/doi.org\/10.3389\/fimmu.2021.728322.","journal-title":"Front Immunol"},{"issue":"1","key":"4063_CR10","doi-asserted-by":"publisher","first-page":"e16098","DOI":"10.1111\/ene.16098","volume":"31","author":"V Bril","year":"2024","unstructured":"Bril V, Howard JF, Karam C, et al. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study. Eur J Neurol. 2024;31(1):e16098. https:\/\/doi.org\/10.1111\/ene.16098.","journal-title":"Eur J Neurol"},{"issue":"10","key":"4063_CR11","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, et al. Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372\u201386. https:\/\/doi.org\/10.1172\/JCI97911.","journal-title":"J Clin Invest"},{"key":"4063_CR12","doi-asserted-by":"publisher","first-page":"1401972","DOI":"10.3389\/fimmu.2024.1401972","volume":"15","author":"G Zhu","year":"2024","unstructured":"Zhu G, Ma Y, Zhou H, et al. Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod. Front Immunol. 2024;15:1401972. https:\/\/doi.org\/10.3389\/fimmu.2024.1401972.","journal-title":"Front Immunol"},{"issue":"8","key":"4063_CR13","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang Q, Zeng W, et al. Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China. Ann Clin Transl Neurol. 2024;11(8):2212\u201321. https:\/\/doi.org\/10.1002\/acn3.52142.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"4063_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325. https:\/\/doi.org\/10.1212\/WNL.0000000000002790.","journal-title":"Neurology"},{"issue":"1","key":"4063_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Jaretzki A, Barohn RJ, et al. Myasthenia gravis: recommendations for clinical research standards. Neurology. 2000;55(1):16\u201323. https:\/\/doi.org\/10.1212\/WNL.55.1.16.","journal-title":"Neurology"},{"issue":"3","key":"4063_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s13760-022-02162-1","volume":"123","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Ozawa Y, Yasuda M, Onishi Y, Akamine H, Kuwabara S. Minimal symptom expression achievement over time in generalized myasthenia gravis. Acta Neurol Belg. 2023;123(3):979\u201382. https:\/\/doi.org\/10.1007\/s13760-022-02162-1.","journal-title":"Acta Neurol Belg"},{"issue":"7","key":"4063_CR17","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","volume":"267","author":"J Vissing","year":"2020","unstructured":"The REGAIN study group, Vissing J, Jacob S, Fujita KP, O\u2019Brien F, Howard JF. Minimal symptom expression\u2019 in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with efgartigimod. J Neurol. 2020;267(7):1991\u20132001. https:\/\/doi.org\/10.1007\/s00415-020-09770-y.","journal-title":"J Neurol"},{"issue":"5","key":"4063_CR18","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/mus.27974","volume":"68","author":"N Katyal","year":"2023","unstructured":"Katyal N, Halldorsdottir K, Govindarajan R, et al. Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Muscle Nerve. 2023;68(5):762\u20136. https:\/\/doi.org\/10.1002\/mus.27974.","journal-title":"Muscle Nerve"},{"issue":"3","key":"4063_CR19","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","volume":"94","author":"B Neumann","year":"2020","unstructured":"Neumann B, Angstwurm K, Mergenthaler P, et al. Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology. 2020;94(3):e299\u2013313. https:\/\/doi.org\/10.1212\/WNL.0000000000008688.","journal-title":"Neurology"},{"issue":"12","key":"4063_CR20","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1007\/s00415-021-10603-9","volume":"268","author":"N K\u00f6nig","year":"2021","unstructured":"K\u00f6nig N, Stetefeld HR, Dohmen C, et al. MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation. J Neurol. 2021;268(12):4824\u201333. https:\/\/doi.org\/10.1007\/s00415-021-10603-9.","journal-title":"J Neurol"},{"key":"4063_CR21","doi-asserted-by":"publisher","first-page":"1212757","DOI":"10.3389\/fimmu.2023.1212757","volume":"14","author":"AG Vakrakou","year":"2023","unstructured":"Vakrakou AG, Karachaliou E, Chroni E, et al. Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease. Front Immunol. 2023;14:1212757. https:\/\/doi.org\/10.3389\/fimmu.2023.1212757.","journal-title":"Front Immunol"},{"key":"4063_CR22","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3389\/fneur.2020.00660","volume":"11","author":"C Rodolico","year":"2020","unstructured":"Rodolico C, Bonanno C, Toscano A, Vita G. MuSK-Associated Myasthenia gravis: clinical features and management. Front Neurol. 2020;11:660. https:\/\/doi.org\/10.3389\/fneur.2020.00660.","journal-title":"Front Neurol"},{"key":"4063_CR23","doi-asserted-by":"publisher","first-page":"175628642098674","DOI":"10.1177\/1756286420986747","volume":"14","author":"S Su","year":"2021","unstructured":"Su S, Liu Q, Zhang X, et al. VNTR2\/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis. Ther Adv Neurol Disord. 2021;14:1756286420986747. https:\/\/doi.org\/10.1177\/1756286420986747.","journal-title":"Ther Adv Neurol Disord"},{"issue":"23","key":"4063_CR24","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard","year":"2019","unstructured":"Howard JF, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661\u201373. https:\/\/doi.org\/10.1212\/WNL.0000000000007600.","journal-title":"Neurology"},{"issue":"7","key":"4063_CR25","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9.","journal-title":"Lancet Neurol"},{"key":"4063_CR26","doi-asserted-by":"publisher","unstructured":"Kawama K, Warabi Y, Bokuda K, Kimura H, Takahashi K. Exacerbation of Thymoma-Associated Myasthenia Gravis following Efgartigimod Treatment related to anti-acetylcholine receptor antibody overshoot: a report of two cases. Cureus Published Online Dec. 2023;17. https:\/\/doi.org\/10.7759\/cureus.50692.","DOI":"10.7759\/cureus.50692"},{"issue":"1","key":"4063_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2567.2006.02408.x","volume":"119","author":"UJH Sachs","year":"2006","unstructured":"Sachs UJH, Socher I, Braeunlich CG, Kroll H, Bein G, Santoso S. A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal fc receptor alpha-chain promoter. Immunology. 2006;119(1):83\u20139. https:\/\/doi.org\/10.1111\/j.1365-2567.2006.02408.x.","journal-title":"Immunology"}],"updated-by":[{"DOI":"10.1186\/s12883-025-04227-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000}}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04063-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04063-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04063-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T05:58:16Z","timestamp":1748152696000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04063-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4063"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04063-1","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the authors reported an error that the term \u201cneonatal intensive care unit\u201d was mistakenly used instead of \u201dNeuro intensive care unit\u201d. The corrections are in article title, Keywords, Introduction section and graphical abstract. Also, abbreviations section has been added after the conclusions.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12883-025-04227-z","URL":"https:\/\/doi.org\/10.1186\/s12883-025-04227-z","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures with human participants\u2019 involvement were following the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This is an observational study, and the local ethics committee for clinical research has confirmed that no ethical approval is required. Before administration of the efgartigimod, we clearly informed the efficacy and AEs of it and fully explained the purpose and content of this study. Moreover, as this is a retrospective study with no additional interventions, the requirement for written informed consent was waived. Every patient who filled out the questionnaire indicated agreement to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients indicated agreement for publication. No personal information of the participants has been disclosed in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}